The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Risks of Paralytic Disease Due to Wild or Vaccine‐Derived Poliovirus After Eradication
Abstract
After the global eradication of wild polioviruses, the risk of paralytic poliomyelitis from polioviruses will still exist and require active management. Possible reintroductions of poliovirus that can spread rapidly in unprotected populations present challenges to policymakers. For example, at least one outbreak will likely occur due to circulation of a neurovirulent vaccine‐derived poliovirus after discontinuation of oral poliovirus vaccine and also could possibly result from the escape of poliovirus from a laboratory or vaccine production facility or from an intentional act. In addition, continued vaccination with oral poliovirus vaccines would result in the continued occurrence of vaccine‐associated paralytic poliomyelitis. The likelihood and impacts of reintroductions in the form of poliomyelitis outbreaks depend on the policy decisions and on the size and characteristics of the vulnerable population, which change over time. A plan for managing these risks must begin with an attempt to characterize and quantify them as a function of time. This article attempts to comprehensively characterize the risks, synthesize the existing data available for modeling them, and present quantitative risk estimates that can provide a starting point for informing policy decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION
Kew, O. M., Sutter, R. W., de Gourville, E. M., Dowdle, W. R., & Pallansch, M. A. (2005) · Annual Review of Microbiology · doi:10.1146/annurev.micro.58.030603.123625 · Cited by 703
Self-citationKew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., André, J., Blackman, E., Freeman, C. J., Jorba, J., et al. (2002) · Science · doi:10.1126/science.1068284 · Cited by 600
Self-citationFactors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review.
Patriarca, P. A., Wright, P. F., & John, T. J. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.5.926 · Cited by 453
Fine, P. E. M., & Carneiro, I. A. M. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009924 · Cited by 247
Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993
Yang, C.-F., Naguib, T., Yang, S.-J., Nasr, E., Jorba, J., Ahmed, N., Campagnoli, R., van der Avoort, H., Shimizu, H., Yoneyama, T., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.15.8366-8377.2003 · Cited by 233
Self-citationProlonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient
Kew, O. M., Sutter, R. W., Nottay, B. K., McDonough, M. J., Prevots, D. R., Quick, L., & Pallansch, M. A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2893-2899.1998 · Cited by 213
Self-citationMartín, J., Dunn, G., Hull, R., Patel, V., & Minor, P. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.7.3001-3010.2000 · Cited by 160
Molecular epidemiology of polioviruses
Kew, O. M., Mulders, M. N., Lipskaya, G. Y., da Silva, E. E., & Patlansch, M. A. (1995) · Seminars in Virology · doi:10.1016/s1044-5773(05)80017-4 · Cited by 157
Self-citationPolio eradication: the OPV paradox
Dowdle, W. R., De Gourville, E., Kew, O. M., Pallansch, M. A., & Wood, D. J. (2003) · Reviews in Medical Virology · doi:10.1002/rmv.401 · Cited by 144 · cited 1×
“To date, investigators detected or investigated no substantial spread beyond the immunodeficient patients in Table III,(90) and consequently, while the evidence provides some information about the prevalence of iVDPV excretors, it offers little information about the likelihood of outbreaks associated with iVDPVs.”
BackgroundSelf-citationRecombinant Vaccine–Derived Poliovirus in Madagascar
Rousset, D., Rakoto-Andrianarivelo, M., Razafindratsimandresy, R., Randriamanalina, B., Guillot, S., Balanant, J., Mauclère, P., & Delpeyroux, F. (2003) · Emerging Infectious Diseases · doi:10.3201/eid0907.020692 · Cited by 138
Bellmunt, A., May, G., Zell, R., Pring-Åkerblom, P., Verhagen, W., & Heim, A. (1999) · Virology · doi:10.1006/viro.1999.0003 · Cited by 128
Khetsuriani, N., Prevots, D. R., Quick, L., Elder, M. E., Pallansch, M., Kew, O., & Sutter, R. W. (2003) · The Journal of Infectious Diseases · doi:10.1086/379791 · Cited by 110 · cited 1×
“Although HIV currently represents the most prevalent form of immunodeficiency, particularly in developing countries, no known iVDPV excretors exist among HIVinfected persons and the risk of prolonged excretion appears low.(28,71,122)”
BackgroundSelf-citationBlomqvist, S., Savolainen, C., Laine, P., Hirttiö, P., Lamminsalo, E., Penttilä, E., Jöks, S., Roivainen, M., & Hovi, T. (2004) · Journal of Virology · doi:10.1128/jvi.78.9.4876-4883.2004 · Cited by 104
Long-term circulation of vaccine-derived poliovirus that causes paralytic disease
Cherkasova, E. A., Korotkova, E. A., Yakovenko, M. L., Ivanova, O. E., Eremeeva, T. P., Chumakov, K. M., & Agol, V. I. (2002) · Journal of Virology · doi:10.1128/jvi.76.13.6791-6799.2002 · Cited by 103
Cherkasova, E., Laassri, M., Chizhikov, V., Korotkova, E., Dragunsky, E., Agol, V. I., & Chumakov, K. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633511100 · Cited by 101
The Biologic Principles of Poliovirus Eradication
Dowdle, W. R., & Birmingham, M. E. (1997) · Journal of Infectious Diseases · doi:10.1093/infdis/175.supplement_1.s286 · Cited by 99
Georgescu, M. M., Balanant, J., Macadam, A., Otelea, D., Combiescu, M., Combiescu, A. A., Crainic, R., & Delpeyroux, F. (1997) · Journal of Virology · doi:10.1128/jvi.71.10.7758-7768.1997 · Cited by 83
Korotkova, E. A., Park, R., Cherkasova, E. A., Lipskaya, G. Y., Chumakov, K. M., Feldman, E. V., Kew, O. M., & Agol, V. I. (2003) · Journal of Virology · doi:10.1128/jvi.77.23.12460-12465.2003 · Cited by 73 · cited 2×
“showed more than 1% VP1 divergence (56)”
BackgroundSelf-citation"Endgame" Issues for the Global Polio Eradication Initiative
Technical Consultative Group to the World Health Organization on the Global Eradication of Poliomyelitis (2002) · Clinical Infectious Diseases · doi:10.1086/338262 · Cited by 61
Hidalgo, S., Erro, M. G., Cisterna, D., & Freire, M. C. (2003) · Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000069792.60744.5b · Cited by 44
Poliovirus Vaccine Shedding among Persons with HIV in Abidjan, Cote d’Ivoire
Hennessey, K. A., Lago, H., Diomande, F., Akoua‐Koffi, C., Caceres, V. M., Pallansch, M. A., Kew, O. M., Nolan, M., & Zuber, P. L. F. (2005) · The Journal of Infectious Diseases · doi:10.1086/498166 · Cited by 39
Self-citation
Cited by
Role of environmental poliovirus surveillance in global polio eradication and beyond
HOVI, T., SHULMAN, L. M., VAN DER AVOORT, H., DESHPANDE, J., ROIVAINEN, M., & DE GOURVILLE, E. M. (2012) · Epidemiology and Infection · doi:10.1017/s095026881000316x · Cited by 318
“tial source of circulating neurovirulent VDPV strains [35].”
BackgroundEngineering attenuated virus vaccines by controlling replication fidelity
Vignuzzi, M., Wendt, E., & Andino, R. (2008) · Nature Medicine · doi:10.1038/nm1726 · Cited by 282
Platt, L. R., Estivariz, C. F., & Sutter, R. W. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu184 · Cited by 267
“Large pools of susceptible populations can accumulate in all age groups through historically low OPV coverage and absence of natural immunity from wild poliovirus in polio-free regions [43].”
BackgroundSelf-citationBurns, C. C., Shaw, J., Jorba, J., Bukbuk, D., Adu, F., Gumede, N., Pate, M. A., Abanida, E. A., Gasasira, A., Iber, J., et al. (2013) · Journal of Virology · doi:10.1128/jvi.02954-12 · Cited by 153
Self-citationImplications of a circulating vaccine-derived poliovirus in Nigeria
Jenkins, H. E., Aylward, R. B., Gasasira, A., Donnelly, C. A., Mwanza, M., Corander, J., Garnier, S., Chauvin, C., Abanida, E., Pate, M. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0910074 · Cited by 131
Self-citation
Metadata
- Authors
- Tebbens, R. J. D., Pallansch, M. A., Kew, O. M., Cáceres, V. M., Jafari, H., Cochi, S. L., Sutter, R. W., Aylward, R. B., & Thompson, K. M.
- Venue
- Risk Analysis
- Publisher
- Wiley
- Published
- 2006-11-15
- Volume
- 26
- Issue
- 6
- Pages
- 1471-1505
- ISSN
- 0272-4332 (ISSN-L)
- 1539-6924
- OpenAlex
- W2156920603
- Cited by
- 174
- References
- 21
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.